Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients

MLA

Natalie Andrews Wright, et al. “Tumor Molecular Profiling to Differentiate Extreme Responses to First-Line Platinum-Based Chemotherapy in Suboptimally Debulked Serous Ovarian Cancer Patients.” Journal of Clinical Oncology, vol. 36, May 2018, p. 5561. EBSCOhost, https://doi.org/10.1200/jco.2018.36.15_suppl.5561.

APA

Natalie Andrews Wright, Paola Marco-Casanova, Bryan Lo, Alberto Diaz de Leon, Harmanjatinder S. Sekhon, Darren Hodgson, William J. Howat, Johanne I Weberpals, Doreen Whelan, Dax Torti, Marc Duciaume, Kayla Marsh, Jonathon Torchia, Prisni Rath, Martine P. Roudier, Trevor J. Pugh, Glenwood D. Goss, Gemma N Jones, & Laurence Bernard. (2018). Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients. Journal of Clinical Oncology, 36, 5561. https://doi.org/10.1200/jco.2018.36.15_suppl.5561

Chicago

Natalie Andrews Wright, Paola Marco-Casanova, Bryan Lo, Alberto Diaz de Leon, Harmanjatinder S. Sekhon, Darren Hodgson, William J. Howat, et al. 2018. “Tumor Molecular Profiling to Differentiate Extreme Responses to First-Line Platinum-Based Chemotherapy in Suboptimally Debulked Serous Ovarian Cancer Patients.” Journal of Clinical Oncology 36 (May): 5561. doi:10.1200/jco.2018.36.15_suppl.5561.